Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
Key result
Renin-angiotensin-aldosterone system (RAAS) inhibitors are underused in older patients with HFrEF, and their effectiveness in this population requires confirmation by randomized clinical trials.
Why the study?
Older patients with HFrEF are frequently excluded from clinical trials, and despite guideline recommendations, RAAS inhibitors appear underused in this population due to limited evidence and fear of adverse effects.
Do Renin-angiotensin-aldosterone system (RAAS) inhibitors improve outcomes in older patients with heart failure with reduced ejection fraction (HFrEF)?
Population
Older patients with heart failure with reduced ejection fraction (HFrEF)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Should not yet change practice in older HFrEF patients; leaves open efficacy pending dedicated randomized trials.
Structured PICO
Do Renin-angiotensin-aldosterone system (RAAS) inhibitors improve outcomes in older patients with heart failure with reduced ejection fraction (HFrEF)?
P
Population
Older patients with heart failure with reduced ejection fraction (HFrEF)
I
Intervention
Renin-angiotensin-aldosterone system (RAAS) inhibitors
Despite class I guideline recommendations, RAAS inhibitors are underused in older HFrEF patients due to a lack of dedicated RCT evidence and concerns over adverse effects, highlighting a critical gap in clinical trial representation.
Limitations
- Older patients are frequently excluded from randomised clinical trials, limiting the strength of evidence for this demographic.
Cite This Study
Stolfo et al. (2019) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Renin-angiotensin-aldosterone system (RAAS) inhibitors was evaluated. Renin-angiotensin-aldosterone system (RAAS) inhibitors are underused in older patients with HFrEF, and their effectiveness in this population requires confirmation by randomized clinical trials.